에스티팜

237690KOSDAQ의약품 제조업

57.5 / 100

Reference Date: 2026-04-13

Financial Score21.5 / 40

News Sentiment15.0 / 25

Momentum9.0 / 20

Disclosure12.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Declined 10.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ESTEPAF, originally established as Samcheonri Pharmaceutical in 1983 and later acquired by Dong-A Ssosiogroup in 2010, has expanded into the oligonucleotide CDMO sector, achieving global top 3 production capacity. It entered the mRNA business in 2020, completed the second oligo facility in 2025, and is advancing clinical trials for its self-developed drugs STP0404 (HIV treatment) and STP1002 (cancer treatment). The company has integrated CRO and CDMO services into a one-stop system, enhancing its pharmaceutical development capabilities through global partnerships.

Number of Employees

1,560people

Average Salary

68.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

52.96Industry Average 14.800.0Point

3.6x industry avg (risky)

PBR

5.04Industry Average 1.040.0Point

4.8x industry avg (risky)

ROE

9.96Industry Average 4.427.0Point

2.3x industry avg (excellent)

Debt Ratio

4.18Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 7.4% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 1Negative 0Average Sentiment Score 65

Positive
에스티팜, 유전자 편집 치료제 핵심 'sgRNA' 합성 성공
에스티팜이 유전자 편집 치료제의 핵심인 sgRNA(single guide RNA) 합성에 성공하며 유전자 편집 치료제 시장 진출에 대한 기대감을 높였습니다.
Neutral
韓증시, 불안한 반등…한때 코스피·코스닥 하락 전환
국내 증시가 미국과 이란의 협상 가능성에 장 초반 상승세를 보였으나 지정학적 불확실성으로 상승 폭이 축소되었습니다.

Detailed Momentum

52-week position6.0Point

52w upper range (79%)

Current 143,300Won52-week high 162,10052-week low 71,600

1-month return1.0Point

1m -10.83% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 1Neutral 9Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-30
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-30
Neutral기업설명회(IR)개최2026-03-30
Neutral주식매수선택권부여에관한신고2026-03-26